Thibault Alain

Biography

 Alain has extensive experience in the biopharmaceutical industry, both in the US and Europe. Prior to joining iTeos, Alain was the Chief Medical Officer of arGEN-X, where he oversaw the early development of monoclonal antibodies aimed at immuno-oncology targets, supporting the successful IPO of the company. Earlier, Alain was Vice-President of Oncology at Regeneron Pharmaceuticals where he led the clinical development and approval of VEGF Trap (ZaltrapTM ). Alain has expertise across all stages of biopharmaceutical clinical development, having previously held senior research positions at Johnson & Johnson and Hoffman–La Roche. Alain received his Doctorate of Medicine from McGill University and his certification in medical oncology from the US National Cancer Institute.

Research Interest

Oncology